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Osteoporosis is a common skeletal disease that increases the
risk of fracture, with serious clinical and economic conse-
quences. It can be diagnosed by dual-energy X-ray absorp-
tiometry (DXA), even before a fracture has occurred, using
the World Health Organization (WHO) criteria according
to the patient’s T-score. The WHO has also developed a
fracture risk assessment tool (FRAX) to estimate the 10-year
probability of major osteoporotic fracture (clinical spine,
hip, proximal humerus, and distal forearm) and hip fracture,
using clinical risk factors for fracture and femoral neck
bone mineral density (BMD), if available. Cost-eﬀective
pharmacological agents that have been proven to reduce
fracture risk in patients at high risk for fracture are now
widely available. However, despite great progress in the
management of osteoporosis, it remains a disease that is
underrecognized and undertreated; if treatment is started,
persistence is often poor, with only about 50% of patients
who are prescribed medication for osteoporosis still taking
it 1 year later. Even when treatment is taken correctly and
for a suﬃcient length of time for the patient to beneﬁt
from reduction in fracture risk, there may nevertheless be
limitations in eﬀectiveness (note the lack of evidence for
reduction in the risk of hip fractures or other nonvertebral
fractures with some agents), limitations in the duration
of therapy (e.g., no more than 24 months of lifetime
teriparatide in the US), and concerns regarding long-term
safety, such as atypical femur fractures and osteonecrosis of
the jaw with bisphosphonates. For all of these reasons, the
goal of reducing the global burden of osteoporotic fractures
is not being fully achieved.
This special issue of the Journal of Osteoporosis describes
new and emerging approaches to treatment that oﬀer the
potential to reduce the risk of fractures or manage their
consequences better than what is currently observed in
clinical practice. In recent years, our understanding of
the pathophysiology of osteoporosis and the regulation of
bone remodeling at the molecular level have undergone
tremendous advances, leading to the investigation of drugs
that target speciﬁc molecules in order to modulate the
bone remodeling process. For example, the discovery that
receptor activator of nuclear factor kappa B ligand (RANKL)
is the principal regulator of osteoclastic bone resorption
led to the development of denosumab, a fully human
monoclonal antibody to RANKL. This potent antiresorptive
agent, administered as a 60mg subcutaneous injection every
6 months, recently received regulatory approval for the
treatment of women with postmenopausal osteoporosis
(PMO)athighriskforfracture.Ithasbeenshown toincrease
BMD, reduce bone turnover marker levels, and reduce the
risk of vertebral fractures, hip fractures, and nonvertebral
fractures in women with PMO.
Wnt signaling initiated by the binding of Wnt proteins
to the low density lipoprotein-related protein (LRP5/6)-
frizzled receptor complex has recently been recognized as
an important upregulator of osteoblastic bone formation;
sclerostin and Dickkopf-1 (DKK-1) are natural inhibitors of2 Journal of Osteoporosis
Wnt signaling. In this issue, J. J. Mason and B. O. Williams
describe a rare genetic disorder, sclerosteosis, resulting from
am u t a t i o no ft h eSOST gene that encodes for sclerostin, and
van Buchem disease, a related disorder caused by a mutation
closely linked to SOST on chromosome 17q11.2. Patients
with sclerosteosis and van Buchem disease have high bone
mass due to downregulation of sclerostin, suggesting that a
therapeutic agent that downregulates sclerostin in a control-
lable fashion might be a potent osteoanabolic treatment for
patientswithosteoporosis.MasonandWilliamsreviewmany
of the studies that have enhanced our understanding of the
regulators of Wnt signaling and lead to the investigation of
compounds with potential therapeutic applications through
their eﬀects on sclerostin or DKK1. A fascinating new ﬁnd-
ing, yet to be fully elucidated, is that serotonin produced by
enterochromaﬃn cells in the duodenum also downregulates
Wnt signaling, raising the possibility that modulation of
serotonin production or activity might also be an eﬀective
treatment for patients with osteoporosis. In a related paper
by S. Silverman in this issue, the preclinical and clinical
studies of sclerostin inhibition are presented.
The drugs used to treat osteoporosis are generally
considered to be in 1 of 2 categories—antiresorptive (e.g,
bisphosphonates) or osteoanabolic (e.g., teriparatide). Inter-
estingly, some drugs may “uncouple,” at least in part, the
closely related processes of bone resorption and formation.
Strontium ranelate may be such ad r u g .A n o t h e r ,p e r h a p s ,i s
odanacatib, an investigational agent that inhibits cathepsin
K, a protease produced by osteoclasts that is largely respon-
sible for the degradation of the bone collagen matrix. J.
L. Perez-Castrillon et al. review what is now known about
the role of cathepsin K in health and disease, followed
by data from phase 1 and phase 2 clinical trials with
odanacatib. This drug is currently under investigation in a
large phase 3 clinical trial to evaluate antifracture eﬃcacy
in women with PMO. Other papers in this issue cover new
developmentsconcerning skeletal heath in areas as diverse as
bisphosphonate nanoparticles, melatonin, and thalassemia.
The papersintheissuewere selectedfrommany excellent
submissions. We give our thanks to all authors of these
submissions and to the numerous reviewers who kindly
donated their time and expertise in helping select and revise
those published here.
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